Why the study?
Does neo-adjuvant chemotherapy followed by delayed surgery improve disease-free survival in patients with non-metastatic malignant fibrous histiocytoma of bone in the extremities?
Does neo-adjuvant chemotherapy followed by delayed surgery improve disease-free survival in patients with non-metastatic malignant fibrous histiocytoma of bone in the extremities?
Neoadjuvant chemotherapy followed by delayed surgery allows for a high rate of limb-sparing procedures and favorable disease-free survival in patients with non-metastatic malignant fibrous histiocytoma of bone.
Answers are grounded in this paper and cite their sources.
May support neoadjuvant chemotherapy with delayed surgery for limb salvage; leaves open optimal regimen pending randomized trials.
Between March 1983 and September 1988, 22 patients with non-metastatic malignant fibrous histiocytoma MFH of bone of the extremities were treated with two regimens of neo-adjuvant chemotherapy successively activated. Preoperatively, the patients received moderate doses of methotrexate and cisplatinum-Regimen 1- or high dose methotrexate, cisplatinum and adriamycin-Regimen 2. Cisplatinum was delivered intraarteriously, the other drugs intravenously. Limb salvage surgery was performed in 20 patients, and 2 patients were amputated. The surgical margins were adequate (radical or wide) in 18 cases and inadequate (marginal) in 4. The histologic response to chemotherapy was good (90% or more tumor necrosis) in 8 patients. In both regimens postoperative chemotherapy was tailored according to the grade of necrosis determined by preoperative treatment on the primary tumor. At an average follow-up of 40 months (15-70), 15 patients (68%) remained continuously disease-free and 7 relapsed with metastases. No local recurrences were observed. Regimen 2 was slightly more effective than Regimen 1 in terms of good histologic response (5/10 vs 1/12) and continuous disease-free survival (8/10 vs 7/127). The results demonstrate that, as in osteosarcoma, in non-metastatic malignant fibrous histiocytoma of bone in the extremities a high percentage of patients can be cured with neoadjuvant chemotherapy and that in most of them limb sparing surgery is possible and safe.
No takes yet. Share an insight, caveat, or question.
Bacci et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: